作者
Toby M. Maher,Miguel Angel Bergna,Amy Hajari Case,Won-Il Choi,Mark J. Hamblin,Tejaswini Kulkarni,Jessica E. Shore,Ioannis P. Tomos,Αrgyris Τzouvelekis,David A. Golod,Eric Elenko,YANQIONG ZHANG,Camilla S. Graham,Jin Woo Song,E I Astashkin On Behalf Of The Linkor Study Investigators
摘要
Abstract Rationale: Deupirfenidone (DPF) is a deuterated form of pirfenidone with a differentiated pharmacokinetic profile that enables higher plasma exposure, potentially allowing for improved efficacy and tolerability in individuals with idiopathic pulmonary fibrosis (IPF). Methods: Phase 2b, international, multi-center, randomized, double-blind, active- and placebo-comparator trial investigated the safety, tolerability, and efficacy of DPF 550 mg TID and DPF 825 mg TID compared to placebo and pirfenidone 801 mg TID (PFD). The primary endpoint was the rate of change in forced vital capacity (FVC) over 26 weeks and the key secondary endpoint was the rate of change in FVC percent predicted (FVCpp) over 26 weeks. Additional endpoints included time to disease progression and safety. The primary statistical analyses compared absolute FVC (mL) and FVCpp between the combined arms of DPF and the placebo arm using a Bayesian approach. Secondary statistical analyses used a frequentist approach. Both utilized a mixed model for repeated measures (MMRM), treating time as a continuous variable. Results: 257 patients were enrolled from 14 countries; median age: 72.0; 71.2% male; median baseline FVC (n= 254): 2580.0 mL; and FVCpp: 77.5%. Double-blinded study treatment completion was 80.0%, 68.3%, 64.6%, and 78.1% for placebo, PFD, DPF 550 mg, and DPF 825 mg arms, respectively. Using Bayesian analysis, the posterior probability that the pooled DPF arms had less decline compared to placebo in FVC (mL) was 98.5% and in FVCpp was 99.6%. Using a frequentist analysis, the change from baseline in FVC (mL) and FVCpp over 26 weeks is shown in the Figure. Treatment-emergent adverse events commonly associated with antifibrotics (%) were nausea (7.7, 27.0, 16.9, 20.3), dyspepsia (3.1, 22.2, 12.3, 14.1), diarrhea (9.2, 11.1, 10.8, 7.8), abdominal pain (4.6, 7.9, 6.2, 14.1), photosensitivity reaction (0, 7.9, 6.2, 7.8), decreased appetite (7.7, 14.3, 18.5, 20.3), fatigue (1.5, 11.1, 7.7, 9.4), dizziness (3.1, 7.9, 9.2, 12.5), and headache (4.6, 12.7, 7.7, 3.1) for placebo, PFD, DPF 550 mg, and DPF 825 mg arms, respectively. Conclusions: Deupirfenidone met both FVC and FVCpp endpoints in the primary Bayesian approach and a dose response between 550 mg and 825 mg was demonstrated. DPF 825 mg also met both endpoints, demonstrated statistical significance by a frequentist approach, and had an FVC decline that approached the level seen with the normal aging process. Deupirfenidone was well tolerated at both doses and safety was consistent with previous studies. These data support continued development of deupirfenidone in patients with IPF.